Takeda has agreed to divest two of its non-core assets in a bid to streamline its portfolio to focus on its four core business areas. Novartis is set to receive Takeda’s dry-eye disease medication, Xiidra®(lifitegrast ophthalmic solution), in exchange for up to US$5.3 B; whereas, Ethicon is to acquire TachoSil® Fibrin Sealant Patch for approximately US$400 M. The deals are the first in Takeda’s strategy to reduce the more than US$30 B in debt the company took on to fund the takeover of Shire which completed in January 2019.